Stage IV Squamous Cell Carcinoma of the Nasopharynx Completed Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0028783 (Stage IV Squamous Cell Carcinoma of the Nasopharynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00939627Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabTreatment
NCT00096512S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerTreatment